Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review
J Alijotas-Reig, E Esteve-Valverde, C Belizna… - Autoimmunity …, 2020 - Elsevier
Abstract Severe Acute Respiratory Syndrome related to Coronavirus-2 (SARS-CoV-2),
coronavirus disease-2019 (COVID-19) may cause severe illness in 20% of patients. This …
coronavirus disease-2019 (COVID-19) may cause severe illness in 20% of patients. This …
Pharmaco-immunomodulatory therapy in COVID-19
The severe acute respiratory syndrome coronavirus 2 associated coronavirus disease 2019
(COVID-19) illness is a syndrome of viral replication in concert with a host inflammatory …
(COVID-19) illness is a syndrome of viral replication in concert with a host inflammatory …
Immunomodulation as treatment for severe coronavirus disease 2019: a systematic review of current modalities and future directions
EA Meyerowitz, P Sen, SR Schoenfeld… - Clinical Infectious …, 2021 - academic.oup.com
In severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, viral load
peaks early and declines quickly after symptom onset. Severe coronavirus disease 2019 …
peaks early and declines quickly after symptom onset. Severe coronavirus disease 2019 …
Immunomodulatory drugs in the management of SARS-CoV-2
DR Burrage, S Koushesh, N Sofat - Frontiers in immunology, 2020 - frontiersin.org
With the onset of the global pandemic in 2020 of Severe Acute Respiratory Syndrome
Coronavirus-2 (SARS-CoV-2), there has been increasing research activity around certain …
Coronavirus-2 (SARS-CoV-2), there has been increasing research activity around certain …
Immunology, immunopathogenesis and immunotherapeutics of COVID-19; an overview
LM Khosroshahi, M Rokni, T Mokhtari… - International …, 2021 - Elsevier
Abstract Coronavirus disease 2019 (COVID-19) infection which is caused by severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2) has led to a “public health emergency of …
respiratory syndrome coronavirus-2 (SARS-CoV-2) has led to a “public health emergency of …
Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider
A Alunno, A Najm, X Mariette, G De Marco… - Annals of the …, 2021 - ard.bmj.com
Objective To summarise the available information on efficacy and safety of
immunomodulatory agents in SARS-CoV-2 infection. Methods As part of a European …
immunomodulatory agents in SARS-CoV-2 infection. Methods As part of a European …
Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions
The coronavirus disease-19 pandemic (COVID-19), which appeared in China in December
2019 and rapidly spread throughout the world, has forced clinicians and scientists to take up …
2019 and rapidly spread throughout the world, has forced clinicians and scientists to take up …
Immunomodulation as a potent COVID-19 pharmacotherapy: Past, present and future
DM Hertanto, BS Wiratama, H Sutanto… - Journal of …, 2021 - Taylor & Francis
In the first year of its appearance, the 2019 coronavirus disease (COVID-19) has affected
more than 150 million individuals and killed 3 million people worldwide. The pandemic has …
more than 150 million individuals and killed 3 million people worldwide. The pandemic has …
Immunomodulation for severe COVID-19 pneumonia: the state of the art
Y Zhang, Y Chen, Z Meng - Frontiers in immunology, 2020 - frontiersin.org
COVID-19 has become a worldwide pandemic caused by the novel coronavirus named
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Severe cases of COVID-19 …
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Severe cases of COVID-19 …
Immune responses during COVID-19 infection
C Melenotte, A Silvin, AG Goubet, I Lahmar… - …, 2020 - Taylor & Francis
Over the past 16 years, three coronaviruses (CoVs), severe acute respiratory syndrome CoV
(SARS-CoV) in 2002, Middle East respiratory syndrome CoV (MERS-CoV) in 2012 and …
(SARS-CoV) in 2002, Middle East respiratory syndrome CoV (MERS-CoV) in 2012 and …